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Abstract. The cancer stem cell (CSC) marker CD133 is 
widely expressed in gliomas and employed mostly by use of 
the CD133/1 antibody which binds the extracellular glycosyl-
ated AC133 epitope. CD133 recognition may, however, be 
affected by its glycosylation pattern and oxygen tension. The 
present study investigates the effect of oxygen deprivation on 
CD133 expression and glycosylation status employing a high 
AC133-expressing glioblastoma multiforme (GBM) cell line, 
IN699. IN699 cells were cultured under normoxic (21% O2) and 
hypoxic (3% O2) conditions. CD133 expression was analysed by 
western blotting (WB), qRT-PCR, immunocytochemistry (ICC) 
and flow cytometry using the glycosylation-specific antibody 
CD133/1 and ab19898 which binds the unglycosylated intra-
cellular residues of CD133. By flow cytometry, ab19898 detected 
94.1% and 96.2% CD133+ cells under normoxia and hypoxia, 
respectively. Hypoxia significantly increased the percentage 
of CD133+ cells from 69% to 92% using CD133/1 (p<0.005). 
Moreover, a significantly higher geomean fluorescence intensity 
(GMI) was demonstrated by ab19898 (p<0.005) in CD133+ cells. 
WB and qRT-PCR results were consistent with flow cytometry 
data. Furthermore, over a period of 72-h incubation under 
normoxic and hypoxic conditions after autoMACS sorting, an 
average of 31.8% and 42.2%, respectively, of CD133-negative 
IN699 cells became positive using CD133/1. Our data show that 
a) previously reported CD133- cells may have been misidenti-
fied using the glycosylation-specific CD133/1 as constitutive 
expression of CD133 was detected by the intracellular antibody 
ab19898; b) hypoxia promotes glycosylation status of CD133, 
indicating possible involvement of glycosylated CD133 in the 
process of anti-hypoxia-mediated apoptosis.
Introduction
CD133 was first presented as a key marker for brain tumour 
stem cells (BTSCs) in 2003 when in vitro experiments indi-
cated that CD133+ cells possess significantly enhanced ability 
to differentiate, proliferate and self-renew. The research also 
showed CD133+ cells could generate new malignancies that 
were phenotypically and histologically similar to the tumour 
of origin (1). However, since these findings were published, 
other researchers have been able to demonstrate tumourigenesis 
by CD133- cells and challenged the role of CD133 in tumour 
initiation (2,3). Despite the controversy, the link between CD133 
and tumourigenesis has remained a ‘hot’ topic in CSC research 
(4-6). Current evidence also indicates that CD133 expression in 
CSCs differs according to cell cycle phases in vitro, although 
stem cell potency and differentiating capabilities are preserved 
(7). Indeed, CD133 expression, and thus perhaps also glycosyl-
ation, fluctuates during the cell cycle, being low in quiescent 
cells in G0 or G1 but higher in subsequent phases (7). This 
has important implications for using CD133 to enrich CSCs as 
non-dividing invading cells and other quiescent cells within the 
tumour mass could be missed by immunological detection of 
CD133. 
Several splice variants of CD133 have been identified in 
man (8). This has potential impact on the CSC detection as 
CD133 may be present but lacking the antibody specific epitope 
so cells could be described falsely as CD133-. Indeed, it has 
been reported that CD133- glioblastoma cells (determined by 
CD133/1 antibody) express a truncated variant of the protein 
(9). Post-translational glycosylation of CD133 may also 
affect antibody detection since the commonly used antibody, 
CD133/1, is likely to detect CD133-expressing cells only when 
the epitope AC133 is glycosylated, causing concerns over 
the limitations of glycosylated CD133 epitopes in isolating 
CSCs (10). Furthermore, the role of CD133 in brain tumour 
biology must be elucidated with consideration of the tumour 
microenvironment. Hypoxic microenvironment is a feature 
of glioblastoma multiforme (GBM), the most common and 
malignant of primary glial tumours in the brain (11). Hypoxia 
is believed to trigger BTSC proliferation and invasion as 
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well as to promote resistance to therapy (12,13). It has been 
demonstrated by us and others, using the CD133/1 antibody, 
that CD133 expression increases under hypoxic culture condi-
tions (14-17), suggesting a similar CD133 expression pattern 
in vivo. A recent study shows that enhanced expression of 
OCT3/4 (octamer-binding transcription factor 3/4) and SOX2 
(SRY-box containing gene 2) by HIF-1α (hypoxia-inducible 
factor 1α) and HIF-2α (hypoxia-inducible factor 2α) is required 
for hypoxia-induced CD133 expression in cultured human lung 
cancer cells (18). The study also reveals the direct binding of 
OCT4 and SOX2 to the P1 promoter of CD133 gene, further 
elucidating the underlying mechanism since P1 is most strongly 
associated with hypoxia-induced promoter activity of CD133 
transcription (18). However, although it is widely accepted that 
hypoxia enhances CD133 expression, it is not yet well under-
stood how the immunodetection of CD133 may be affected 
by oxygen tension. A recent study demonstrates inconsistent 
CD133 immunostaining patterns in glioblastoma tissues using 
four different antibody clones, reflecting different binding sites 
as well as glycosylation status. Yet the implication of normoxic 
and hypoxic CD133+ niches remains unclear (19). In this 
research we set out to investigate the possibility that CD133 
glycosylation might be influenced by different oxygen tensions 
and that this may, in turn, determine the true expression of 
CD133 in glioma-derived cell populations.
We have previously reported the biological and molecular 
characteristics of one unique paediatric GBM cell line, IN699, 
which contains an unusually high population of CD133-positive 
cells, where parent culture and the CD133+/CD133- subpopula-
tions derived therefrom under normoxic and hypoxic culture 
conditions were subject to thorough investigation (14). Our data 
from immunocytochemistry and flow cytometry using neural 
stem cell specific antigenic markers indicate similar stemness 
and differentiation capacities of both CD133+ and CD133- cells. 
Molecular cytogenetic study also shows identical genomic 
imbalances between CD133+ and CD133- fractions. Under 
hypoxic conditions, CD133+ cells demonstrated a significantly 
enhanced proliferative rate whereas a significant increase in 
invasive propensity was observed in the CD133- cells. Further-
more, hypoxia promoted CD133 expression associated with 
phenotype of poorly differentiated cells with cancer stem cell 
markers (14). In the present study, we further investigated whether 
CD133 glycosylation was regulated by changes in oxygen 
tension and how hypoxia might affect the immuno detection 
of CD133. Using western blotting (WB), flow cytometry and 
immunocytochemistry (ICC), changes in CD133 expression 
and glycosylation under normoxic and hypoxic conditions were 
demonstrated by CD133/1 and another commercially available 
CD133 antibody (ab19898, see below) in early passage biopsy-
derived IN699 cells. 
Materials and methods
Cell line. IN699 cells (passages 14-19) known to contain a high 
proportion of CD133/1+ cells were used in this study (14). Cells 
were cultured in Neurobasal-A medium (Fisher Scientific, 
Loughborough, UK) with supplements under normoxic (21% 
oxygen) and hypoxic (3% oxygen) conditions as described in 
previous studies (14,20). Cells were grown to 90% confluency 
before experimental use. 
Antibodies
Primary antibodies. Ab19898 (Abcam, Cambridge, UK) 
recognises the intracellular unglycosylated amino acid residues 
848-865 of CD133 near the C-terminus. It was used in WB 
(1:100), ICC (1:200) and flow cytometry (1:100) to investigate 
the presence of the CD133 protein.
CD133/1 (W6B3C1) pure for WB (1:200) and CD133/1 
(AC133) pure for ICC (1:200) and flow cytometry (1:50) were 
purchased from Miltenyi-biotec Ltd. (Surrey, UK). Both anti-
bodies recognise the glycosylated amino acid residues 508-792 
on the extracellular loops of CD133. They were used to detect 
changes in CD133 glycosylation under normoxic and hypoxic 
conditions. The binding sites of both CD133 primary antibodies 
are illustrated in Fig. 1. Anti-actin (Sigma-Aldrich, Dorset, UK) 
was used as a control in the WB experiment (1:1000).
Secondary antibodies. Horseradish peroxidase (HRP)-
conjugated IgG (Invitrogen/Life Technologies Ltd., Paisley, 
UK) was used for chemiluminescent detection in WB (1:1000). 
Fluorochrome-conjugated AlexaFluor-488 and -568 (Invitrogen/
Life Technologies Ltd.) were used in flow cytometry (1:500) and 
ICC (1:500). 
Western blotting (WB). Western blotting was performed 
according to standard protocol. Briefly, cell lysates (20 µg 
of protein) from normoxic and hypoxic IN699 cells were 
separated in the ‘any kDa’ pre-cast gel (Bio-Rad Laboratories 
Ltd., Hemel Hempstead, UK) and transblotted onto a polyvi-
nylidene difluoride membrane (GE Healthcare Life Sciences, 
Little Chalfont, UK). Proteins were detected using the corre-
sponding primary antibody and horseradish peroxidase-linked 
secondary antibodies; the blot was visualized by chemilumi-
nescence (Interchim SA/Cheshire Sciences Ltd., Chester, UK) 
with the GBOX Chemi XT16 software (Syngene, Cambridge, 
UK). 
Quantitative real-time PCR (qRT-PCR). The mRNA level of 
CD133 in IN699 cells (normoxic and hypoxic) was quantified 
by qRT-PCR using TaqMan Gene Expression Assay with prede-
signed probe spanning the exon 9-10 junction, which detects all 
CD133 transcript variants reported in humans (8). The assay was 
performed on the ABI 7500 Real-Time PCR System (Applied 
Biosystems/Life Technologies Ltd.). The expression of CD133 
was normalised to that of the endogenous gene, β-actin, served 
as an internal control. The relative quantification of CD133 in 
normoxic and hypoxic IN699 cells was carried out using the 
2-ΔΔCt method (21).
ICC. ICC was carried out following established procedure in 
our laboratory (14). For the intracellular antibody (ab19898) 
detection, cells were permeabilised with 0.02% Triton X-100 
(Sigma-Aldrich) at 4˚C for 10 min. Permeabilised and non-
permeabilised cells were then incubated with the relevant 
primary antibody (ab19898 and CD133/1) at room tempera-
ture for 1 h, following another 30-min incubation with the 
corresponding secondary antibody. Hoechst Blue (1:200) 
(Sigma-Aldrich) nuclear counterstain was added to each well 
and the coverslips were then mounted on microscope slides 
with a small drop of VectorShield mounting medium (Vector 
Laboratories Ltd., Orton Southgate, UK). The slides were 
observed using a Zeiss Axio Imager Epifluorescence micro-
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scope (Carl Zeiss Ltd., Welwyn Garden City, UK). Images 
were captured using Velocity software (V5.2, Perkin-Elmer, 
Cambridge, UK).
Flow cytometry. Flow cytometry was performed with CD133/1 
and ab19898 in three independent experiments as described 
previously (14). For the extracellular primary antibody 
CD133/1, normoxic and hypoxic IN699 cells were incubated 
with CD133/1 at 4˚C for 30 min excluding the control samples. 
Then the anti-mouse secondary antibody AlexaFluor-488 was 
added to all samples and the cells were incubated at 4˚C for 
another 15 min. After incubation the cells were resuspended 
in 1% goat serum/PBS (Sigma-Aldrich) and transferred to 
fluorescence-activated cell sorting (FACS) tubes. The analysis 
was carried out on a FACSCalibur (BD Bioscience, Oxford, 
UK) and propidium iodide (PI) (Sigma-Aldrich) was added to 
each tube shortly before analysis in order to enable cell viability 
correction. For the intracellular primary antibody ab19898, cells 
were permeabilised with Cytofix/Cytoperm™ (BD Bioscience) 
at 4˚C for 20 min before adding ab19898. The remaining steps 
were identical to those for the non-permeabilised cells, except 
that no PI was added prior to visualisation. 
Automated magnetic cell sorting (autoMACS). CD133-expres-
sing cells were sorted using the automated magnetic cell 
sorting system (autoMACS™) (Miltenyi Biotec) (14). Briefly, 
IN699 cells were labelled with CD133/1 antibody conjugated 
to a magnetic microbead (Miltenyi Biotec) and separated into 
CD133/1-positive and negative populations. The negative cells 
were subcultured under normoxic and hypoxic conditions then 
harvested at 24, 48 and 72-h time points to analyse CD133/1 
expression by flow cytometry.
Statistics. Statistical evaluation was carried out by Student's 
t-test for qRT-PCR and flow cytometry data analysis. A p-value 
of <0.05 was taken as significant.
Results
Analysis of CD133 expression by WB and qRT-PCR. WB was 
used to semi-quantitatively determine the presence of CD133 in 
normoxic and hypoxic cells. The blot was probed with ab19898 
Figure 1. Illustration of the binding sites of CD133/1 and ab19898 [modified from Taïeb et al (25)]. Glycosylation sites are indicated by black circles. E1-3, extra-
cellular loops; M1-5, transmembrane domains; C1-3, intracellular loops.
Figure 2. Analysis of CD133 expression in IN699 cells. A, Western blotting 
with CD133/1 and ab19898. All lanes show actin around the expected 48 kDa 
marker and CD133 around 120 kDa. Lanes 1 and 2, CD133/1 for normoxic (N) 
and hypoxic (H) cell lysates; lanes 3 and 4, ab19898 for normoxic and hypoxic 
cell lysates. B, qRT-PCR detection of CD133 mRNA level in normoxic (N) 
and hypoxic (H) IN699 cells when normalised against the internal control 
β-actin. Error bars indicate the standard deviation.
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and CD133/1 (W6B3C1) for CD133 detection and actin was 
used as a control (Fig. 2A). Comparison between CD133 bands 
detected with CD133/1 indicates an increase in glycosylated 
CD133 under hypoxic conditions whereas ab19898 detected 
similar amounts of CD133 under both conditions. The expres-
sion of CD133 was further investigated at mRNA level using 
qRT-PCR. In accordance with WB, CD133 mRNA was detected 
at similar levels in both normoxic and hypoxic cells when CD133 
expression was normalised against that of the internal control 
gene, β-actin (p=0.343; Fig. 2B).
Immunostaining of CD133. ICC images demonstrated the 
intracellular staining by ab19898 whereas CD133/1 stained 
extracellularly giving a clear outline of the cells (Fig. 3).
Quantification of CD133 by flow cytometry. The IN699 cells 
were further characterised with CD133/1 (AC133) and ab19898 
antibodies by flow cytometry to establish the percentage of 
CD133+ cells by the MFI (mean fluorescence intensity) and 
the average expression level of the protein in individual cells 
by GFI (geomean fluorescence intensity). In accordance with 
Figure 3. Representative ICC images of CD133 staining in IN699 cells (scale bar, 32 µm). Nucleus is stained blue with DAPI (4',6-diamidino-2-phenylindole); 
the primary antibodies ab19898 and CD133/1 were visualised by green-fluorescence (AlexaFluor-488).
Figure 4. Comparison of MFI and GFI between CD133/1 and ab19898. A and B, MFI and GFI of both antibodies detected in normoxic IN699 cells; C and D, MFI 
and GFI of both antibodies detected in hypoxic IN699 cells. Error bars indicate the standard deviation.
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previous data (14), CD133/1 detected 67.5% and 94.5% of 
CD133+ cells under normoxic and hypoxic culture conditions 
respectively (Fig. 4A and C; p<0.005). The GFI associated with 
the antigen binding sites significantly increased in hypoxia 
(Fig. 4B and D; p<0.005). On the contrary, flow cytometry with 
ab19898 showed a similar percentage of CD133+ cells under 
both culture conditions (Fig. 4A and C; p=0.157). Similarly, 
no significant difference was demonstrated by GFI (Fig. 4B 
and D; p=0.0844). Compared with CD133/1, ab19898 detected 
a higher percentage of CD133+ cells as well as a much stronger 
expression level of the protein per cell in normoxic IN699 cells 
(Fig. 4A and B; p<0.005). Interestingly, under hypoxic condi-
tions, both antibodies detected a similar positive proportion 
as indicated by MFI (p=0.0786) whereas GFI suggested that 
a significant increase in the average expression level of CD133 
was present using ab19898 (p<0.005) (Fig. 4C and D). 
In order to further investigate the effect of oxygen tension 
on CD133 glycosylation status, CD133/1-negative IN699 cells 
were sorted by the autoMACS technique and cultured under 
normoxic and hypoxic conditions over the period of 24, 48 
and 72 h. Cells were then analysed by flow cytometry using 
CD133/1 antibody. Interestingly, 48.0%, 17.9% and 29.4% of 
the ‘negative’ population were detected as positive respectively 
at each time point within the normoxic cell group, using the 
same antibody used for cell sorting, i.e., CD133/1. There was 
no obvious difference in GFI amongst the time points, with the 
average value of 8.79 (p=0.422) (data not shown). Under hypoxic 
conditions, 49.7%, 36.1% and 40.8% of the ‘negative’ population 
were detected positive respectively, with the average GFI of 8.48 
(p=0.357) (data not shown). Thus, at 48 and 72-h hypoxia was 
shown to strongly promote the glycosylation status of CD133.
Discussion
Collectively, our WB and qRT-PCR data suggest that CD133 
is constitutively expressed while flow cytometry results indi-
cate that the glycosylation status of the protein is enhanced by 
hypoxia. Furthermore, glycosylation of CD133 fluctuates during 
in vitro culture under both normoxic and hypoxic conditions. 
Previous studies using CD133/1 under normoxic conditions 
may have only detected a fraction of CD133-expressing cells, 
implying that the previously categorised CD133- cells with 
tumour-initiating properties may have actually been undetected 
CD133+ cells. Our flow cytometry data indicate that a constitutive 
expression of CD133 exists in IN699 cells regardless of oxygen 
stress but CD133 glycosylation is enhanced by oxygen depletion 
although only a small proportion of the protein is glycosylated 
in individual cells. This could be that the machinery producing 
and moving mature molecules to the surface is saturated or that 
there is only a certain amount of glycosylated CD133 on the cell 
membrane at any given time.
In order to study CD133+ cells as BTSCs their behaviour 
must be investigated under conditions close to those in vivo. 
Analysing CD133+ cells under hypoxic conditions, as in this 
study, advances knowledge in this field. The broadly used 
CD133/1 antibody has been shown in this study to rely on the 
glycosylation status of CD133, which in normoxia would yield 
a much lower population of CD133+ cells than in hypoxia. This 
study supports the results that hypoxia elevates the number of 
CD133+ cells (17), although the connection with shortcomings 
of the CD133/1 antibody approach was not made in previous 
studies. Such studies have also failed to show whether the total 
amount of CD133 expressed per cell increases under hypoxic 
conditions, irrespective of glycosylation status. This could 
have been demonstrated effectively if a non-glycosylation 
dependent antibody like ab19898 had been used, as our data 
suggest that although hypoxia enhances CD133 glycosylation, 
a proportion of the molecule remains unglycosylated in the 
CD133-expressing IN699 cells. Therefore this study shows that 
the immunodetection of CD133 using CD133/1 is affected by 
glycosylation status of the protein, providing an explanation 
for the previous contradictory results regarding tumourigenic 
properties of CD133+ and CD133- cells (2,3). 
The present study also questions the widely used CD133/1 
as the antibody of choice to isolate entire CD133+ popula-
tions, although CD133/1 may still be useful in elucidating the 
biological function of the glycosylated CD133. Based on our 
observations, ab19898 should be more effective than CD133/1 
in enriching CD133+ cells in glioma, be they CSCs or not, 
as the former is not only glycosylation-independent, but also 
binds the intracellular, and thus probably immature, protein 
in cells that may not be expressing cell surface CD133 at the 
time. Moreover, different splice variants of CD133 may have 
different glycosylation patterns and it is unknown how this 
could affect the immunological detection of CD133 using 
glycosylation-dependent antibodies (22). The suggestion that 
CD133/1 has limitations in detecting CD133 is supported by 
findings that the AC133 epitope recognised by CD133/1 is lost 
during cancer stem cell differentiation, although the expression 
level of CD133 protein remains the same (23), as well as by a 
recent study in which a truncated variant of the protein was 
detected in glioblastoma cells negative for CD133/1 antibody 
(9). On the other hand, the glycosylated CD133 protein on the 
cell surface is more likely to be mature with defined biological 
function and capability of interacting with extracellular 
messenger molecules (24), e.g., the ganglioside GD3 which is 
overexpressed on glioma cells and plays important regulatory 
roles in apoptosis and invasion (25,26). Therefore CD133/1 
could be valuable in elucidation of the functional significance 
of CD133 glycosylation and its impact on CSC biology, filling 
the knowledge gap surrounding glycosylation patterns during 
cell proliferation and differentiation.
To our knowledge, this is the first time that hypoxia has 
been shown to enhance CD133 glycosylation, although hypoxia-
induced CD133 expression has been demonstrated previously 
(14-17,27). Although a previous study using tissue sections of 
glioma revealed differences in CD133 expression based upon 
antibody used (19), ours is the first study whereby the defined 
population of CD133+ or CD133- glioblastoma cells was used to 
establish the influence of hypoxic conditions on CD133 glyco-
sylation using different antibodies. Moreover, it is known that 
hypoxia promotes cancer cell invasion and distant metastasis, 
including that in gliomas (28-30), and recently upregulation 
of CD133 under hypoxic conditions has also been associated 
with increased aggressiveness of pancreatic cancer cells (31). 
In addition, the critical roles that mitochondria play in cancer 
development and progression have long been recognised (32-35) 
and accumulating evidence supports the ‘cross-talking’ relation-
ship between mitochondria and HIF-1 in protecting cancer cells 
from hypoxia-mediated apoptosis (36-40). Therefore, based on 
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studies by us and other researchers, we hypothesise that glycosyl-
ated CD133 may interact with GD3 (as mentioned above) and/or 
other unknown modulators to promote glioma stem cell survival 
and invasiveness during hypoxia-triggered apoptosis, mediated 
by signal pathways involving HIF-1α and mitochondria (16,25-
27,36-42). This hypothetic involvement of glycosylated CD133 
in the ‘pro-survival’ feature of hypoxic CSCs is further mirrored 
by observations where CD133-positive cells show enhanced 
resistance against pro-apoptotic chemotherapy drugs (43,44).  
Furthermore, it is unlikely that there is one ideal CSC marker 
which can be detected on all cells at any given time and under 
any condition. In the case of CD133, rather than evaluating it 
as a CSC marker, it might be more pertinent to understand its 
biological function in tumour development and progression.
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